The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. User asks if RU58841 powder mixed in stemoxydine needs refrigeration and if it maintains quality at room temperature like pre-mixed solutions.
A 22-year-old male experienced hair loss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.
The user is experiencing noticeable hair improvement after 4.5 months of using a treatment regimen including minoxidil, finasteride, biotin, Nioxin shampoo, microneedling, topical NANoxidil, and copper peptides. Feedback from others is positive, encouraging the user to continue the treatment for at least a year or more.
A user with diffuse thinning, currently using finasteride, biotin, minoxidil, and nizoral shampoo, is considering a topical solution called "82M" but is skeptical due to its high cost and lack of supporting research. They seek others' experiences with "82M."
A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.
A user with diffuse thinning shares a tip for improving hair appearance by using a shea butter and coconut oil serum from Trader Joe's at night. They are on finasteride and considering adding minoxidil for better results.
A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.
The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
The conversation discusses the potential benefits of sublingual minoxidil for hair loss treatment. It suggests that sublingual minoxidil, which bypasses the liver, may have fewer side effects, greater bioavailability, and could be more effective than oral minoxidil.
RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.
The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.
The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.
Eucapill 2% used for 1 month reduced shedding from 200 to 10/20 hairs daily with no side effects. Finasteride caused side effects like ED and watery semen.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
Be skeptical of claims about new baldness cures; current treatments like finasteride, dutasteride, and minoxidil remain the best options. New products like Breezula and PP405 lack compelling evidence and may not be available soon.
People are humorously discussing unconventional and extreme methods of using hair loss treatments like finasteride and minoxidil, including vaping, snorting, and injecting. The conversation is filled with jokes and sarcasm about these methods.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The user experienced reduced effectiveness of minoxidil after consistent use, despite using dutasteride to maintain hair. They are considering alternatives like microneedling and exploring options like hair transplants due to dissatisfaction with current hair density.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.